共 88 条
[1]
Laverdierre M(2000)Impact of fluconazole prophylaxis on fungal colonization and infection rates in neutropenic patients J Antimicrob Chemother 46 1001-1008
[2]
Rotstein C(1998)The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis. An autopsy study of 355 patients Medicine (Baltimore) 77 246-254
[3]
Bow EJ(2007)Posaconazole vs fluconazole or itraconazole prophylaxis in patients with neutropenia N Engl J Med 356 348-359
[4]
van Burik JH(2012)Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period Haematologia 97 459-463
[5]
Leisenring W(2018)Breakthrough fungal infections in patients with leukemia receiving isavuconazole Clin Infect Dis 67 1610-1612
[6]
Myerson D(2018)Risk factors and clinical outcomes of breakthrough yeast bloodstream infections in patients with hematological malignancies in the era of newer antifungal agents Med Mycol 56 197-206
[7]
Cornely OA(2018)Breakthrough candidemia after the introduction of broad spectrum antifungal agents: a 5-year retrospective study Med Mycol 56 406-415
[8]
Maertens J(2018)Breakthrough invasive mold infections in the hematology patient: current concepts and future directions Clin Infect Dis 67 1621-1630
[9]
Winston DJ(2012)Invasive breakthrough infections, fungal colonization and emergence of resistant strains in high-risk patients receiving antifungal prophylaxis with posaconazole: real-life data from a single-centre institutional retrospective observational study J Antimicrob Chemother 67 2268-2273
[10]
Anadah-Rajah MR(2016)A cohort study on breakthrough invasive fungal infections in high-risk patients receiving antifungal prophylaxis J Antimicrob Chemother 71 2634-2641